

# David A Vesey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3763289/publications.pdf>

Version: 2024-02-01

100  
papers

3,452  
citations

136950

32  
h-index

155660

55  
g-index

104  
all docs

104  
docs citations

104  
times ranked

4319  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between inÂvitro and inÂvivo effects. <i>Biochemical and Biophysical Research Communications</i> , 2022, 586, 42-48.	2.1	5
2	Effects of Environmental Exposure to Cadmium and Lead on the Risks of Diabetes and Kidney Dysfunction. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2259.	2.6	21
3	Progress curve analysis of microtitre plate plasma clotting assays. Assessment of tissue factor levels. <i>Analytical Biochemistry</i> , 2021, 614, 114060.	2.4	0
4	The Effect of Cadmium on GFR Is Clarified by Normalization of Excretion Rates to Creatinine Clearance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1762.	4.1	10
5	PAR2 Activation on Human Kidney Tubular Epithelial Cells Induces Tissue Factor Synthesis, That Enhances Blood Clotting. <i>Frontiers in Physiology</i> , 2021, 12, 615428.	2.8	7
6	Expression of protease activated receptor-2 is reduced in renal cell carcinoma biopsies and cell lines. <i>PLoS ONE</i> , 2021, 16, e0248983.	2.5	3
7	The Evolving Role for Zinc and Zinc Transporters in Cadmium Tolerance and Urothelial Cancer. <i>Stresses</i> , 2021, 1, 105-118.	4.8	5
8	PAR2-Induced Tissue Factor Synthesis by Primary Cultures of Human Kidney Tubular Epithelial Cells Is Modified by Glucose Availability. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7532.	4.1	2
9	Gender Differences in Zinc and Copper Excretion in Response to Co-Exposure to Low Environmental Concentrations of Cadmium and Lead. <i>Stresses</i> , 2021, 1, 3-15.	4.8	4
10	Establishing a stable platform for the measurement of blood endotoxin levels in the dialysis population. <i>Diagnosis</i> , 2021, 8, 249-256.	1.9	4
11	A cost-effective three-dimensional culture platform functionally mimics the adipose tissue microenvironment surrounding the kidney. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 736-742.	2.1	4
12	Cadmium and Lead Exposure, Nephrotoxicity, and Mortality. <i>Toxics</i> , 2020, 8, 86.	3.7	99
13	Development of a Biomarker Panel to Distinguish Risk of Progressive Chronic Kidney Disease. <i>Biomedicines</i> , 2020, 8, 606.	3.2	9
14	A Comparison of the Nephrotoxicity of Low Doses of Cadmium and Lead. <i>Toxics</i> , 2020, 8, 18.	3.7	22
15	Proteaseâ€activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidney. <i>Nephrology</i> , 2019, 24, 983-991.	1.6	3
16	The Source and Pathophysiologic Significance of Excreted Cadmium. <i>Toxics</i> , 2019, 7, 55.	3.7	20
17	Chronic exposure to cadmium is associated with a marked reduction in glomerular filtration rate. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 468-475.	2.9	24
18	GRP78 expression in tumor and perinephric adipose tissue is not an optimal risk stratification marker for clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2019, 14, e0210246.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Biomarkers and the role of mast cells as facilitators of inflammation and fibrosis in chronic kidney disease. <i>Translational Andrology and Urology</i> , 2019, 8, S175-S183.	1.4	21
20	The inverse association of glomerular function and urinary $\hat{I}^{2}$ -MG excretion and its implications for cadmium health risk assessment. <i>Environmental Research</i> , 2019, 173, 40-47.	7.5	21
21	Pharmacological inhibition of protease-activated receptor-2 reduces crescent formation in rat nephrotoxic serum nephritis. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 456-464.	1.9	8
22	Dysbiosis of the Duodenal Mucosal Microbiota Is Associated With Increased Small Intestinal Permeability in Chronic Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00068.	2.5	13
23	Indoxyl Sulfate Induces Apoptosis and Hypertrophy in Human Kidney Proximal Tubular Cells. <i>Toxicologic Pathology</i> , 2018, 46, 449-459.	1.8	33
24	Role of the unfolded protein response in determining the fate of tumor cells and the promise of multi-targeted therapies. <i>Cell Stress and Chaperones</i> , 2018, 23, 317-334.	2.9	17
25	Is renal tubular cadmium toxicity clinically relevant?. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 681-687.	2.9	11
26	Conditioned medium from stimulated macrophages inhibits growth but induces an inflammatory phenotype in breast cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 247-254.	5.6	12
27	Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?. <i>Pathology</i> , 2018, 50, 504-510.	0.6	10
28	Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells. <i>Journal of Kidney Cancer and VHL</i> , 2018, 5, 1-9.	1.0	8
29	Current health risk assessment practice for dietary cadmium: Data from different countries. <i>Food and Chemical Toxicology</i> , 2017, 106, 430-445.	3.6	145
30	Kidney Cadmium Toxicity, Diabetes and High Blood Pressure: The Perfect Storm. <i>Tohoku Journal of Experimental Medicine</i> , 2017, 241, 65-87.	1.2	93
31	Health Risk Assessment of Dietary Cadmium Intake: Do Current Guidelines Indicate How Much is Safe?. <i>Environmental Health Perspectives</i> , 2017, 125, 284-288.	6.0	131
32	Maslinic Acid Inhibits Proliferation of Renal Cell Carcinoma Cell Lines and Suppresses Angiogenesis of Endothelial Cells. <i>Journal of Kidney Cancer and VHL</i> , 2017, 4, 16-24.	1.0	30
33	Factors associated with acutely elevated serum creatinine following radical tumour nephrectomy: the Correlates of Kidney Dysfunction—Tumour Nephrectomy Database study. <i>Translational Andrology and Urology</i> , 2017, 6, 899-909.	1.4	4
34	The stress response of human proximal tubule cells to cadmium involves up-regulation of haemoxygenase 1 and metallothionein but not cytochrome P450 enzymes. <i>Toxicology Letters</i> , 2016, 249, 5-14.	0.8	14
35	Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 47-53.	2.1	6
36	PAR2 Modulators Derived from GB88. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 1179-1184.	2.8	12

#	ARTICLE	IF	CITATIONS
37	Tu1709 Altered Proximal Small-Intestinal Permeability and Bacterial Translocation in Chronic Liver Disease in Relation to Hepatic Fibrosis and Disease Severity. <i>Gastroenterology</i> , 2016, 150, S1169.	1.3	2
38	Differential Anti-inflammatory Activity of HDAC Inhibitors in Human Macrophages and Rat Arthritis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 387-396.	2.5	41
39	Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 986-991.	2.2	4
40	Higher Dialysate Matrix Metalloproteinase-2 Levels are Associated with Peritoneal Membrane Dysfunction. <i>Peritoneal Dialysis International</i> , 2016, 36, 16-25.	2.3	8
41	Indoxyl sulphate and kidney disease: Causes, consequences and interventions. <i>Nephrology</i> , 2016, 21, 170-177.	1.6	56
42	Thimerosal induces apoptotic and fibrotic changes to kidney epithelial cells <i>in vitro</i> . <i>Environmental Toxicology</i> , 2015, 30, 1423-1433.	4.0	6
43	Baseline Serum Interleukin-6 Predicts Cardiovascular Events in Incident Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 35-42.	2.3	23
44	P0541 : Small intestinal permeability is elevated in chronic viral hepatitis prior to the development of cirrhosis, and is associated with the degree of fibrosis. <i>Journal of Hepatology</i> , 2015, 62, S518.	3.7	0
45	Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The BAL Anz Trial. <i>Peritoneal Dialysis International</i> , 2015, 35, 159-171.	2.3	7
46	Increased progression to kidney fibrosis after erythropoietin is used as a treatment for acute kidney injury. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, F681-F692.	2.7	35
47	Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10424-10442.	6.4	19
48	Protein-bound Uremic Toxins, Inflammation and Oxidative Stress: A Cross-sectional Study in Stage 3-4 Chronic Kidney Disease. <i>Archives of Medical Research</i> , 2014, 45, 309-317.	3.3	137
49	Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. <i>BMC Nephrology</i> , 2014, 15, 8.	1.8	46
50	Pathway-selective antagonism of proteinase activated receptor 2. <i>British Journal of Pharmacology</i> , 2014, 171, 4112-4124.	5.4	54
51	Fibronectin and transforming growth factor beta contribute to erythropoietin resistance and maladaptive cardiac hypertrophy. <i>Biochemical and Biophysical Research Communications</i> , 2014, 444, 332-337.	2.1	7
52	Functional significance of erythropoietin in renal cell carcinoma. <i>BMC Cancer</i> , 2013, 13, 14.	2.6	38
53	PAR2-induced inflammatory responses in human kidney tubular epithelial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, F737-F750.	2.7	40
54	Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney. <i>Journal of Nephropathology</i> , 2013, 2, 154-65.	0.2	18

#	ARTICLE	IF	CITATIONS
55	An antagonist of human protease activated receptor $\alpha$ 2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen $\alpha$ induced arthritis in rats. <i>FASEB Journal</i> , 2012, 26, 2877-2887.	0.5	91
56	Patient samples of renal cell carcinoma show reduced expression of TRAF1 compared with normal kidney and functional studies in vitro indicate TRAF1 promotes apoptosis: potential for targeted therapy. <i>Pathology</i> , 2012, 44, 453-459.	0.6	22
57	Antagonism of Protease-Activated Receptor 2 Protects against Experimental Colitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 256-265.	2.5	83
58	Evidence for Steroidogenic Potential in Human Prostate Cell Lines and Tissues. <i>American Journal of Pathology</i> , 2012, 181, 1078-1087.	3.8	29
59	BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4639-4644.	2.2	12
60	Transport pathways for cadmium in the intestine and kidney proximal tubule: Focus on the interaction with essential metals. <i>Toxicology Letters</i> , 2010, 198, 13-19.	0.8	138
61	Erythropoietin Protects Against Acute Kidney Injury and Failure. <i>The Open Drug Discovery Journal</i> , 2010, 2, 8-17.	0.7	8
62	Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3674-3678.	2.2	53
63	Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3669-3673.	2.2	45
64	Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3664-3668.	2.2	46
65	Isolation and Primary Culture of Human Proximal Tubule Cells. <i>Methods in Molecular Biology</i> , 2009, 466, 19-24.	0.9	34
66	BACE-1 inhibitors Part 1: Identification of novel hydroxy ethylamines (HEAs). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1011-1016.	2.2	45
67	BACE-1 inhibitors part 2: Identification of hydroxy ethylamines (HEAs) with reduced peptidic character. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1017-1021.	2.2	55
68	BACE-1 inhibitors part 3: Identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1022-1026.	2.2	62
69	Second Generation of Hydroxyethylamine BACE-1 Inhibitors: Optimizing Potency and Oral Bioavailability. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3313-3317.	6.4	62
70	Proinflammatory and proliferative responses of human proximal tubule cells to PAR-2 activation. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F1441-F1449.	2.7	19
71	Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. <i>Cancer Biology and Therapy</i> , 2007, 6, 1944-1950.	3.4	26
72	Apoptosis of tubulointerstitial chronic inflammatory cells in progressive renal fibrosis after cancer therapies. <i>Translational Research</i> , 2007, 150, 40-50.	5.0	21

#	ARTICLE	IF	CITATIONS
73	Design, synthesis, and antiviral properties of 4- $\epsilon$ -substituted ribonucleosides as inhibitors of hepatitis C virus replication: The discovery of R1479. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 2570-2576.	2.2	92
74	Silibinin inhibits renal cell carcinoma via mechanisms that are independent of insulin-like growth factor-binding protein 3. <i>BJU International</i> , 2007, 99, 454-460.	2.5	13
75	Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin-like growth factor binding protein-3 levels. <i>BJU International</i> , 2007, 100, 438-444.	2.5	24
76	Potential physiological and pathophysiological roles for protease-activated receptor-2 in the kidney (Review Article). <i>Nephrology</i> , 2007, 12, 36-43.	1.6	34
77	Isolation, propagation and characterization of primary tubule cell culture from human kidney (Methods in Renal Research). <i>Nephrology</i> , 2007, 12, 155-159.	1.6	38
78	Novel renoprotective actions of erythropoietin: New uses for an old hormone (Review Article). <i>Nephrology</i> , 2006, 11, 306-312.	1.6	54
79	Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. <i>Kidney International</i> , 2006, 69, 1806-1813.	5.2	162
80	Synthesis of Indoles: Efficient Functionalisation of the 7-Position. <i>Synthesis</i> , 2006, 2006, 3467-3477.	2.3	5
81	Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells. <i>Kidney International</i> , 2005, 67, 1315-1329.	5.2	38
82	Role of protein kinase C and oxidative stress in interleukin-1 $\beta$ -induced human proximal tubule cell injury and fibrogenesis. <i>Nephrology</i> , 2005, 10, 73-80.	1.6	8
83	Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas. <i>International Journal of Urology</i> , 2005, 12, 17-28.	1.0	12
84	Synthesis of 3,5,7-Substituted Indoles via Heck Cyclisation. <i>Synlett</i> , 2005, 2005, 3071-3074.	1.8	1
85	Erythropoietin protects against ischaemic acute renal injury. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 348-355.	0.7	251
86	The roles of IGF-I and IGFBP-3 in the regulation of proximal tubule, and renal cell carcinoma cell proliferation. <i>Kidney International</i> , 2004, 65, 1272-1279.	5.2	52
87	Interleukin-1 $\beta$ stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor- $\beta$ -dependent mechanism. <i>Translational Research</i> , 2002, 140, 342-350.	2.3	91
88	Interleukin-1 $\beta$ induces human proximal tubule cell injury, $\alpha$ -smooth muscle actin expression and fibronectin production. <i>Kidney International</i> , 2002, 62, 31-40.	5.2	94
89	Inhibition of proliferation of HT-29 colon adenocarcinoma cells by carboxylate NSAIDs and their acyl glucuronides. <i>Life Sciences</i> , 2001, 70, 37-48.	4.3	9
90	Enalaprilat Directly Ameliorates in vitro Cyclosporin Nephrotoxicity in Human Tubulo-Interstitial Cells. <i>Nephron</i> , 2000, 86, 473-481.	1.8	15

#	ARTICLE	IF	CITATIONS
91	Peritoneal Homocysteine Clearance is Inefficient in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2000, 20, 766-771.	2.3	6
92	Preparation and characterization of polyclonal antibodies against human chaperonin 10. <i>Cell Stress and Chaperones</i> , 2000, 5, 14.	2.9	18
93	Effect of luminal growth factor preservation on intestinal growth. <i>Lancet, The</i> , 1993, 341, 843-848.	13.7	107
94	Down regulation of epidermal growth factor receptors in liver proliferation induced by a mixture of triiodothyronine, amino acids, glucagon, and heparin (TAGH).. <i>Gut</i> , 1993, 34, 1601-1606.	12.1	2
95	Galactosamine induced hepatitis induces a reduction in hepatocyte epidermal growth factor receptors.. <i>Gut</i> , 1992, 33, 954-958.	12.1	2
96	Comparative effects of epidermal growth factor, an insulin-glucagon combination, and a hepatocyte growth factor preparation on epidermal growth factor receptors. <i>Journal of Hepatology</i> , 1992, 15, 107-113.	3.7	9
97	Effect of in vivo administration of an antibody to epidermal growth factor on the rapid increase in DNA synthesis induced by partial hepatectomy in the rat.. <i>Gut</i> , 1992, 33, 831-835.	12.1	11
98	Dose-Dependent Effects of Fentanyl on Indomethacin-Induced Gastric Damage. <i>Digestion</i> , 1991, 49, 198-203.	2.3	21
99	Dimethyl sulphoxide induces a reduced growth rate, altered cell morphology and increased epidermal-growth-factor binding in Hep G2 cells. <i>Biochemical Journal</i> , 1991, 277, 773-777.	3.7	11
100	Gastric output of pancreatic secretory trypsin inhibitor is increased by misoprostol.. <i>Gut</i> , 1991, 32, 1396-1400.	12.1	25